✓ No active regulatory warningsFDA MedWatch, EMA EudraVigilance, WHO VigiBase, WADA Prohibited List · 2026-05-29
📰Read the full Yohimbe / Yohimbine evidence review on GMJ News →Complete clinical article, references and updates on news.gmj.ge. This page is the structured safety summary.⚠ HIGH RISK — see overview [1]
ℹ️ Not obtained from food. Not applicable — this is not obtained from food in meaningful amounts; supplementation is the practical route.
🔬 Lab interpreter
ℹ️ No validated blood test. There is no established laboratory test to assess status or guide dosing for this ingredient. Clinical response and symptoms are the practical guide.
⚕ For professionals — confirm ranges against your local laboratory.
Clinical verdict
Yohimbine is a genuinely potent pharmacological agent (α2-adrenergic antagonist) — one of the few supplements that actually IS a drug. Was FDA-approved (Yocon®) for ED. DANGEROUS as supplement because: (1) bark extract content varies 0–500%; (2) causes hypertension, tachycardia, panic attacks; (3) MAOI + yohimbine = hypertensive crisis. Also studied for fat loss (stubborn fat mobilization) at 0.2 mg/kg. The gap between therapeutic and toxic doses is narrow [1].
1 How much do I need?
👤 Adults: Specific dosage data under clinical review
👴 Elderly: Specific dosage data under clinical review
🤰 Pregnancy: See guidance
CONTRAINDICATED — sympathomimetic; hypertension; uterotonic [1].
👦 Pediatric: See guidance
Not recommended [1].
🏃 Athletes: Standard dose
⚖️ Obesity: Standard dose
Fat-soluble compounds may require dose adjustment in obesity.
🩺 Renal: Consult specialist
Dose adjustment may be needed in renal impairment.
🌱 Vegan: Standard dose
How to take
🍽 Timing: See overview [1].
💊 With food: See overview [1].
🚫 Avoid: See overview for contraindications [1].
2 Which form?
| Form | Bioavailability | Vegan | Cost |
|---|---|---|---|
| ['Various', 'see overview', 'See overview for forms and risks [1].'] | Standard | Check label |
3 Common questions
Key safety point ▼
Yohimbine is a genuinely potent pharmacological agent (α2-adrenergic antagonist) — one of the few supplements that actually IS a drug. Was FDA-approved (Yocon®) for ED. DANGEROUS as supplement because: (1) bark extract content varies 0–500%; (2) causes hypertension, tachycardia, panic attacks; (3) MAOI + yohimbine = hypertensive crisis. Also studied for fat loss (stubborn fat mobilization) at 0.2 mg/kg. The gap between therapeutic and toxic doses is narrow [1].
4 Clinical evidence
Strong
See overview [1]. HIGH
Moderate
See overview [1]. MODERATE
Insufficient
See overview [1]. LOW
5 Safety, toxicity & adverse events
Absolute contraindications
✕ Cardiovascular disease, hypertension or arrhythmia — causes hypertension, tachycardia and arrhythmia
✕ Anxiety/panic disorder, PTSD — can provoke severe anxiety
✕ Concurrent MAOIs
Relative
⚠ Antihypertensives, stimulants and many psychiatric drugs
⚠ Kidney or liver disease
⚠ Supplement yohimbe content is often inconsistent/unpredictable
⚠ Pregnancy — avoid
🚩 Red flags
● HIGH RISK — see overview for critical safety alerts [1]
6 Interactions
Drug interactions
MAO inhibitors Major
Mechanism: LIFE-THREATENING: yohimbine + MAOIs = massive norepinephrine surge → hypertensive crisis [1].
7 Cite this page
Vancouver: Pkhakadze G. Yohimbe / Yohimbine — safety profile [Internet]. Tbilisi: PHIG; 2026 [cited 2026 Sep 01]. Available from: https://supplement.ge/ingredients/yohimbe-yohimbine/
APA 7th: Pkhakadze, G. (2026). Yohimbe / Yohimbine — Safety profile. Public Health Institute of Georgia. https://supplement.ge/ingredients/yohimbe-yohimbine/
📋 Editorial information
Author: Prof. G. Pkhakadze, MD, MPH, PhD
Institution: Public Health Institute of Georgia (PHIG)
Affiliation: David Tvildiani Medical University (DTMU)
First published: January 2026
Last reviewed: 2026-05-29
Next review: March 2027
References: 2 cited sources
COI: SupplementIndex receives no funding from supplement manufacturers. All content independently authored by PHIG.
Process: Systematic literature review
📄 License & reuse
Published under Creative Commons Attribution 4.0 International (CC BY 4.0). You may share and adapt for any purpose with attribution.
Pkhakadze G. "Yohimbe / Yohimbine — Safety Profile." SupplementIndex, PHIG, 2026. https://supplement.ge/ingredients/yohimbe-yohimbine/ CC BY 4.0.
GP
Prof. G. Pkhakadze, MD, MPH, PhD
Professor of Public Health · Head of Department, DTMU
Editor-in-Chief, Georgian Medical Journal (ISSN 3088-4322)
Chair, Public Health Institute of Georgia · UEMS Public Health Section
Educational and public health purposes. CC BY 4.0. Consult your healthcare provider before starting any supplement. Corrections: info@accreditation.ge. Publisher: PHIG